UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.10, sa.2, ss.56-62, 2011 (Hakemli Dergi)
Prostate-specific antigen screening has led to a dramatically increased detection of small-volume, low grade and organ-confined prostate cancer. In an era where active surveillance is now considered a feasible alternative for low-risk prostate cancer patients, it is possible that organ-sparing treatments like focal treatments options (HIFU, CSAP vs.) could also be good treatment alternatives in selected patient groups. Focal therapy is an appealing strategy for any tumor and in time may prove to be a valuable treatment option for low-risk, carefully selected prostate cancer patients.